Single‐ascending dose and food effect studies to assess safety and pharmacokinetics of ainuovirine, a novel non‐nucleoside reverse transcriptase inhibitor, for treatment of HIV‐1 infection

Documenti analoghi

• Single‐dose pharmacokinetics and safety of ACC017, a novel HIV integrase inhibitor, in healthy adult participants: A first‐in‐human study
  di: C. Hu, et al.
  Pubblicazione: (2025)
• Safety, pharmacokinetics and antiviral activity of ainuovirine as 10‐day monotherapy in treatment‐naïve adults with HIV‐1
  Pubblicazione: (2024)
• Effect of fluconazole on the pharmacokinetics of ainuovirine in healthy adult subjects
  Pubblicazione: (2024)
• Effect of food on pharmacokinetics of ACC017, a novel HIV‐1 integrase inhibitor, in healthy adult subjects
  di: C. Hu, et al.
  Pubblicazione: (2025)
• Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants
  di: Jean‐Yves Gillon, et al.
  Pubblicazione: (2025)